Verona Pharma at Jefferies Conference: COPD Drug Exceeds Expectations

Verona Pharma (VRNA) presented at the Jefferies Global Healthcare Conference, highlighting the successful launch of its COPD treatment, O2Ver, which has outperformed previous COPD drug launches with Q1 sales reaching $71 million, a significant increase from Q4's $37 million. The company is expanding its sales force and employing direct-to-patient marketing to further accelerate growth, aiming for increased prescribing depth and new patient starts, while maintaining strong payer access with most patients paying less than $10 out-of-pocket. Verona Pharma is also exploring new indications for ensifentrine, including asthma and cystic fibrosis, and considering acquisitions in the pulmonary/respiratory space to enhance its capabilities, with future profits being invested in pipeline programs, including Phase 2 studies for non-CF bronchiectasis.

Analysis

Verona Pharma (NASDAQ:VRNA) reported significant positive momentum for its COPD treatment, O2Ver, during its presentation at the Jefferies Global Healthcare Conference. The drug's launch has surpassed expectations and outperformed previous COPD treatments, with sales escalating from $37 million in Q4 to $71 million in Q1. This growth is underpinned by strong patient adherence, evidenced by 60% of Q1 dispensed prescriptions being refills, and favorable payer access, with the majority of patients incurring out-of-pocket costs below $10. Management anticipates the gross-to-net adjustment will stabilize in the mid to upper teens. Strategically, Verona Pharma is expanding its commercial footprint by adding 30 new sales representatives by July 1, 2025, and intensifying direct-to-patient marketing efforts targeting 45,000 physicians. The company highlighted that a 1% market share in the COPD space could translate to approximately $1 billion in sales, underscoring the significant market opportunity. Future growth drivers include accelerated sales anticipated in the second half of 2025, reinvestment of profits into pipeline programs such as Phase 2 studies for non-CF bronchiectasis, and the exploration of new indications for ensifentrine, including asthma and cystic fibrosis. Verona Pharma is also actively considering acquisitions within the pulmonary/respiratory domain to bolster its clinical and commercial capabilities, and views O2Ver's pharmacology as complementary, rather than competitive, with existing biologic treatments.

Key Decisions for Investors

• Given O2Ver's strong initial sales trajectory ($71M in Q1), high refill rates (60%), and strategic expansion initiatives, investors should monitor for continued revenue growth and market share capture, particularly following the sales force expansion in H2 2025.
• Investors should track the progression of Verona Pharma's pipeline, including the Phase 2 non-CF bronchiectasis program and any advancements in expanding ensifentrine's indications, as these represent significant long-term value drivers.
• Consider the company's capital allocation strategy, including reinvestment in R&D and potential M&A in the pulmonary/respiratory space, which could further enhance its market position and growth prospects, while also noting the expected gross-to-net stabilization.
• Evaluate the impact of direct-to-patient marketing and positive physician feedback on prescription depth and new patient starts, as these are key elements to achieving the company's ambitious sales targets in the large COPD market.